RCS - Futura Medical PLC - Eroxon to be available on prescription

Futura MedicalAnnouncement

14/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240214:nRSN0287Da&default-theme=true

RNS Number : 0287D  Futura Medical PLC  14 February 2024

RNS Reach

14 February 2024

 

Futura Medical plc

("Futura" or the "Company")

Eroxon to be available on prescription

 as well as over the counter

 

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon,
that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, confirms that its
lead product, Eroxon, will be available on prescription in England and Wales
for the treatment of Erectile Dysfunction ("ED") with effect from 1(st) March
2024. Eroxon is also available without a doctor's prescription having launched
in the UK in March 2023.

 

James Barder, CEO of Futura, commented:

"This milestone builds on the strong progress the Company has made since the
initial launch of Eroxon in the UK and is a further step in improving
availability of Eroxon, providing access by prescription for men with ED as
well as over the counter."

 

Contacts:

 Futura Medical plc             James Barder               investor.relations@futuramedical.com

                          (mailto:Investor.relations@futuramedical.com)
                                Chief Executive Officer

                          +44 (0)1483 685 670
                                Angela Hildreth

                          www.futuramedical.com (http://www.futuramedical.com/)
                                Finance Director and COO

 Alma Strategic Communications  Rebecca Sanders-Hewett     +44 (0)20 3405 0205

                                Sam Modlin                 futura@almastrategic.com

                                Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon. Our core strength lies in our
research, development and commercialisation of topically delivered gel
formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the
treatment of Erectile Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant unmet needs
in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe. Eroxon has been nominated for a number
of healthcare industry awards and has won two to-date.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRGDDUBBDGSX